High-Grade Osteosarcoma of the Foot: Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients.
- Schuster AJ Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany.
- Kager L St. Anna Children's Hospital, Department of Paediatrics, Medical University of Vienna and Children's Cancer Research Institute (CCRI), Vienna, Austria.
- Reichardt P Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
- Baumhoer D Bone Tumour Reference Centre (BTRC), Institute of Pathology, University Hospital of Basel and University of Basel, Basel, Switzerland.
- Csóka M 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary.
- Hecker-Nolting S Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany.
- Lang S Department of Pathology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria.
- Lorenzen S Department of Hematology and Oncology, Klinikum rechts der Isar Technische Universität München, Munich, Germany.
- Mayer-Steinacker R Department of Internal Medicine III, University of Ulm, Ulm, Germany.
- von Kalle T Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatric Radiology, Klinikum Stuttgart, Stuttgart, Germany.
- Kevric M Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany.
- Werner M Department of Interdisciplinary Oncology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
- Windhager R Department of Orthopaedics, Medical University of Vienna, Vienna, Austria.
- Wirth T Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics, Division of Pediatric Orthopedics, Klinikum Stuttgart, Stuttgart, Germany.
- Bielack SS Center for Pediatric, Adolescent and Women's Medicine, Olgahospital, Department of Pediatrics 5 (Oncology, Hematology, Immunology), Klinikum Stuttgart, Stuttgart, Germany.
- 2018-06-02
Published in:
- Sarcoma. - 2018
English
Osteosarcoma of the foot is a very rare presentation of a rare tumor entity. In a retrospective analysis, we investigated tumor- and treatment-related variables and outcome of patients registered in the Cooperative Osteosarcoma Study Group (COSS) database between January 1980 and April 2016 who suffered from primary high-grade osteosarcoma of the foot. Among the 23 eligible patients, median age was 32 years (range: 6-58 years), 10 were female, and 13 were male. The tarsus was the most commonly affected site (n=16). Three patients had primary metastases. All patients were operated: 5 underwent primary surgery and 18 received surgery following preoperative chemotherapy. In 21 of the 23 patients, complete surgical remission was achieved. In 4 of 17 patients, a poor response to neoadjuvant chemotherapy was observed in the resected primary tumors. Median follow-up was 4.2 years (range: 0.4-18.5). At the last follow-up, 15 of the 23 patients were alive and 8 had died. Five-year overall and event-free survival estimates were 64% (standard error (SE) 12%) and 54% (SE 13%), which is similar to that observed for osteosarcoma in general. Event-free and overall survival correlated with primary metastatic status and completeness of surgery. Our findings show that high-grade osteosarcoma in the foot has a similar outcome as osteosarcoma of other sites.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1155/2018/1632978
- PMID 29853778
- Persistent URL
- https://sonar.ch/global/documents/93929
Statistics
Document views: 25
File downloads:
- Full-text: 0